Astellas seeks FDA approval for tacrolimus NDA for prophylaxis of organ rejection
Astellas Pharma US, Inc. ("Astellas"), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for tacrolimus ...
Astellas Submits US New Drug Application for Tacrolimus Extended Release ...MarketWatch (press release)

all 10 news articles »